These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 15775792

  • 21. Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy.
    Kim MJ, Song JH, Suh JH, Lee SW, Kim GA.
    Yonsei Med J; 2003 Jun 30; 44(3):463-72. PubMed ID: 12833584
    [Abstract] [Full Text] [Related]

  • 22. Effects of combination therapy with an angiotensin converting enzyme inhibitor and thiazide diuretic on insulin action in essential hypertension.
    Hunter SJ, Harper R, Ennis CN, Crothers E, Sheridan B, Johnston GD, Atkinson AB, Bell PM.
    J Hypertens; 1998 Jan 30; 16(1):103-9. PubMed ID: 9533423
    [Abstract] [Full Text] [Related]

  • 23. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H, Kanno Y, Nakamoto H, Okada H, Sugahara S.
    Clin Exp Hypertens; 2005 Jan 30; 27(2-3):129-38. PubMed ID: 15835375
    [Abstract] [Full Text] [Related]

  • 24. Sodium-sensitive variability of the antiproteinuric efficacy of RAS inhibitors in outpatients with IgA nephropathy.
    Suzuki T, Miyazaki Y, Shimizu A, Ito Y, Okonogi H, Ogura M, Utsunomiya Y, Kawamura T, Hosoya T.
    Clin Nephrol; 2009 Oct 30; 72(4):274-85. PubMed ID: 19825333
    [Abstract] [Full Text] [Related]

  • 25. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial.
    Ferraro PM, Ferraccioli GF, Gambaro G, Fulignati P, Costanzi S.
    Nephrol Dial Transplant; 2009 Jan 30; 24(1):156-60. PubMed ID: 18685141
    [Abstract] [Full Text] [Related]

  • 26. [Successful treatment of combination therapy using an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker in a patient with IgA nephropathy].
    Horino T, Ito H, Tanimoto N, Yoshida T, Sasaoka A, Chijiwa T, Hosokawa T, Hashimoto K.
    Nihon Jinzo Gakkai Shi; 2003 Jan 30; 45(2):104-8. PubMed ID: 12703406
    [Abstract] [Full Text] [Related]

  • 27. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial.
    Minutolo R, Gabbai FB, Borrelli S, Scigliano R, Trucillo P, Baldanza D, Laurino S, Mascia S, Conte G, De Nicola L.
    Am J Kidney Dis; 2007 Dec 30; 50(6):908-17. PubMed ID: 18037091
    [Abstract] [Full Text] [Related]

  • 28. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
    Cheng G, Liu D, Margetts P, Liu L, Zhao Z, Liu Z, Tang L, Fang Y, Li H, Guo Y, Chen F, Liu F.
    Nephrology (Carlton); 2015 Feb 30; 20(2):77-84. PubMed ID: 25358874
    [Abstract] [Full Text] [Related]

  • 29. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
    Luño J, Barrio V, Goicoechea MA, González C, de Vinuesa SG, Gómez F, Bernis C, Espinosa M, Ahijado F, Gómez J, Escalada P.
    Kidney Int Suppl; 2002 Dec 30; (82):S47-52. PubMed ID: 12410855
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial.
    Derosa G, Maffioli P, D'Avino M, Sala C, Mugellini A, Vulpis V, Felis S, Guasti L, Sarzani R, Bestetti A, Vanasia M, Gaudio G, ESCAPE-IT Trial Investigators group.
    Cardiovasc Ther; 2017 Feb 30; 35(1):47-54. PubMed ID: 27860389
    [Abstract] [Full Text] [Related]

  • 31. Prognostic relevance of clinical and histological features in IgA nephropathy treated with steroid and angiotensin receptor blockers.
    Choi S, Lee D, Jeong KH, Moon JY, Lee SH, Lee TW, Ihm CG.
    Clin Nephrol; 2009 Nov 30; 72(5):353-9. PubMed ID: 19863877
    [Abstract] [Full Text] [Related]

  • 32. Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial.
    Jo YI, Na HY, Moon JY, Han SW, Yang DH, Lee SH, Park HC, Choi HY, Lim SD, Kie JH, Lee YK, Shin SK.
    Korean J Intern Med; 2016 Mar 30; 31(2):335-43. PubMed ID: 26874511
    [Abstract] [Full Text] [Related]

  • 33. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria.
    Kincaid-Smith P, Fairley K, Packham D.
    Nephrol Dial Transplant; 2002 Apr 30; 17(4):597-601. PubMed ID: 11917051
    [Abstract] [Full Text] [Related]

  • 34. Does the hyperfiltration of minoxidil result in increased proteinuria and loss of renoprotection conferred by angiotensin inhibition?
    Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB.
    Kidney Blood Press Res; 2006 Apr 30; 29(1):54-9. PubMed ID: 16645303
    [Abstract] [Full Text] [Related]

  • 35. Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study.
    Hayashi M, Uchida S, Kawamura T, Kuwahara M, Nangaku M, Iino Y, PROTECT-CKD Study Group.
    Clin Exp Nephrol; 2015 Oct 30; 19(5):925-32. PubMed ID: 25680887
    [Abstract] [Full Text] [Related]

  • 36. Evaluation of arterial stiffness in morning hypertension under high-dose valsartan compared to valsartan plus low-dose diuretic.
    Takami T.
    Hypertens Res; 2009 Dec 30; 32(12):1086-90. PubMed ID: 19779491
    [Abstract] [Full Text] [Related]

  • 37. Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients.
    Guasti L, Gaudio G, Lupi A, D'Avino M, Sala C, Mugellini A, Vulpis V, Felis S, Sarzani R, Vanasia M, Maffioli P, Derosa G.
    Drug Des Devel Ther; 2017 Dec 30; 11():2293-2300. PubMed ID: 28831241
    [Abstract] [Full Text] [Related]

  • 38. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].
    Qiu YG, Yao XY, Tao QM, Zheng P, Chen JZ, Zhu JH, Zhang FR, Zheng LR, Zhao LL.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug 30; 25(8):710-4. PubMed ID: 15555399
    [Abstract] [Full Text] [Related]

  • 39. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.
    Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta MM.
    Am J Kidney Dis; 2001 Jul 30; 38(1):18-25. PubMed ID: 11431176
    [Abstract] [Full Text] [Related]

  • 40. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
    Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, Ebihara I, Koide H.
    Am J Nephrol; 2000 Jul 30; 20(5):373-9. PubMed ID: 11092994
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.